AKR1C3 silencing inhibits autophagy‐dependent glycolysis in thyroid cancer cells by inactivating ERK signaling
Authors:
- 4 January 2024
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 85 (1) , e22142
Abstract
Thyroid cancer is a highly differentiated and poorly malignant tumor. Interfering with glycolysis has become an effective means of controlling cancer progression and autophagy is negatively correlated with glycolysis. Aldo‐keto reductase family 1 member C3 (AKR1C3) has been demonstrated to be highly expressed in thyroid cancer tissue and the higher AKR1C3 expression predicted the worse prognosis. We aimed to explore whether AKR1C3 could affect thyroid cancer progression by regulating autophagy‐dependent glycolysis. AKR1C3 expression in thyroid cancer cells was detected by western blot. Then, AKR1C3 was knocked down by transfection with short hairpin RNA specific to AKR1C3 in the absence or presence of 3‐methyladenine (3‐MA) or PMA treatment. Cell cycle and apoptosis was detected by flow cytometry. Immunofluorescence staining was used to analyze LC3B expression. Extracellular acidification, glucose uptake and lactic acid secretion were detected. To evaluate the tumorigenicity of AKR1C3 insufficiency on thyroid cancer in vivo, TPC‐1 cells with AKR1C3 knockdown were injected subcutaneously into nude mice. Then, cyclinD1 and Ki67 expression in tumorous tissues was measured by immunohistochemical analysis. Apoptosis was assessed by terminal‐deoxynucleoitidyl transferase mediated nick end labeling staining. Additionally, the expression of proteins related to cell cycle, apoptosis, glycolysis, autophagy, and extracellular signal‐regulated kinase (ERK) signaling in cells and tumor tissues was assessed by western blot. Highly expressed AKR1C3 was observed in thyroid cancer cells. AKR1C3 knockdown induced cell cycle arrest and apoptosis of TPC‐1 cells. Besides, autophagy was activated and glycolysis was inhibited following AKR1C3 silencing, and 3‐MA treatment restored the impacts of AKR1C3 silencing on glycolysis. The further experiments revealed that AKR1C3 insufficiency inhibited ERK signaling and PMA application reversed AKR1C3 silencing‐induced autophagy in TPC‐1 cells. The in vivo results suggested that AKR1C3 knockdown inhibited the development of subcutaneous TPC‐1 tumors in nude mice and inactivated the ERK signaling. Collectively, AKR1C3 silencing inhibited autophagy‐dependent glycolysis in thyroid cancer by inactivating ERK signaling.Keywords
This publication has 46 references indexed in Scilit:
- Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2016
- Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cellsOncotarget, 2015
- Autophagy and thyroid carcinogenesis: genetic and epigenetic linksEndocrine-Related Cancer, 2014
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Cyclin-dependent kinases and cell-cycle transitions: does one fit all?Nature Reviews Molecular Cell Biology, 2008
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002
- Identification of a Principal mRNA Species for Human 3 -Hydroxysteroid Dehydrogenase Isoform (AKR1C3) That Exhibits High Prostaglandin D2 11-Ketoreductase ActivityThe Journal of Biochemistry, 1998
- Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis.Molecular Biology of the Cell, 1997
- Molecular Cloning of Human Type 3 3α-Hydroxysteroid Dehydrogenase That Differs from 20α-Hydroxysteroid Dehydrogenase by Seven Amino AcidsBiochemical and Biophysical Research Communications, 1996
- How Cells Cycle Toward CancerScience, 1994